SynthesisFrontiers in immunology2025
Research progress on traditional Chinese medicine compounds in autoimmune-related skin diseases.
Synthesis in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- T cell-targeted immunotherapies for multiple sclerosis: molecular mechanisms to therapeutic perspectives from Traditional Chinese medicine.Acta pharmacologica Sinica · 2026Article
- Review
- From Mechanisms to Clinical Practice: Advances in Vitiligo Treatment Across Western Medicine and Traditional Chinese Medicine.Clinical, cosmetic and investigational dermatology · 2026Review
- Chinese botanical drugs for mitigating epidermal growth factor receptor-targeted therapy-associated cutaneous toxicity: immune mechanisms and translational pathways.Frontiers in pharmacology · 2026Review
- Immunomodulatory functions of ginsenosides in skin diseases: molecular mechanisms and therapeutic prospects.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Autoimmune-related skin diseases such as psoriasis, atopic dermatitis (AD), vitiligo, and Sjögren's syndrome (SjS) are characterized by chronic inflammation, immune dysregulation, and complex pathogenesis. Current therapeutic options are limited by side effects, poor efficacy, and high costs. Traditional Chinese medicine (TCM) compounds have demonstrated promising immunomodulatory, anti-inflammatory, and antioxidant effects, offering a novel alternative for managing these conditions. Objective: To systematically review the pharmacological activities and therapeutic potential of bioactive compounds derived from traditional Chinese medicine in treating autoimmune-related skin diseases. Methods: A comprehensive literature review was conducted, focusing on studies that investigated the efficacy, mechanism, and delivery strategies of TCM-derived compounds. Diseases covered include psoriasis, AD, vitiligo, and SjS. Mechanistic pathways such as JAK/STAT, PI3K/AKT, and NF-κB were evaluated alongside compound-specific delivery systems. Results: Numerous TCM compounds, including curcumin, resveratrol, baicalein, berberine, ginsenosides, and paeoniflorin, exhibited therapeutic effects in preclinical and clinical models. These effects were mediated through various pathways, including inhibition of pro-inflammatory cytokines, restoration of skin barrier function, and modulation of immune cell balance. Nano-based delivery systems further enhanced the stability and bioavailability of these compounds. The compounds also showed potential in reducing oxidative stress and improving melanocyte survival in vitiligo, or restoring glandular secretion in SjS. Conclusion: TCM compounds present a valuable resource for the development of safer and more effective therapies for autoimmune-related skin diseases. Further studies are warranted to clarify their mechanisms, optimize delivery systems, and validate clinical efficacy. These natural compounds represent a promising direction for future dermatological drug discovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.